JNJ-2056 is under clinical development by Johnson & Johnson Innovative Medicine and currently in Phase II for Alzheimer's Disease.

JNJ-2056 is under clinical development by Johnson & Johnson Innovative Medicine and currently in Phase II for Tauopathies.

Several large drugmakers, including Pfizer, Bristol Myers Squibb and Sanofi, increased the list prices of their drugs this ...

Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...

The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); ...

Halozyme's attempt to acquire Evotec was a bold move to diversify revenue, but was ultimately unsuccessful, impacting HALO's ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

J&J’s JNJ stock closed at $145.05 on Friday, quite close to its 52-week low of $142.75. In the past three months, J&J’s stock ...

INR:3760. where is there horse racing today Kain Technology's IPO registration application takes effect and will be listed on the Science and Te ...

INR:5796. most runs in world cup 2019 CSPC Pharmaceutical Group enters the Science and Technology Innovation Board! 15 blockbuster products target a m ...

INR:3668. dhoni 2011 world cup images Hengrui Medicine's Bevacizumab Injection Drug Clinical Trial Approved Sanofi's isatuximab is expected to be appr ...

INR:3388. slots on line National Medical Insurance Bureau: Adopt special reimbursement policies for confirmed patients Hengrui's new oral antifungal drug worth US$1 ...